COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives

被引:0
作者
Masataka Nishiga
Dao Wen Wang
Yaling Han
David B. Lewis
Joseph C. Wu
机构
[1] Stanford Cardiovascular Institute,Department of Medicine
[2] Division of Cardiovascular Medicine,Division of Cardiology, Department of Internal Medicine
[3] Stanford University School of Medicine,Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics
[4] Tongji Hospital,Department of Radiology
[5] Tongji Medical College,undefined
[6] Huazhong University of Science & Technology,undefined
[7] Cardiovascular Research Institute,undefined
[8] Department of Cardiology,undefined
[9] General Hospital of Northern Theater Command,undefined
[10] Stanford University School of Medicine,undefined
[11] Stanford University School of Medicine,undefined
来源
Nature Reviews Cardiology | 2020年 / 17卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Coronavirus disease 2019 (COVID-19), caused by a strain of coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic that has affected the lives of billions of individuals. Extensive studies have revealed that SARS-CoV-2 shares many biological features with SARS-CoV, the zoonotic virus that caused the 2002 outbreak of severe acute respiratory syndrome, including the system of cell entry, which is triggered by binding of the viral spike protein to angiotensin-converting enzyme 2. Clinical studies have also reported an association between COVID-19 and cardiovascular disease. Pre-existing cardiovascular disease seems to be linked with worse outcomes and increased risk of death in patients with COVID-19, whereas COVID-19 itself can also induce myocardial injury, arrhythmia, acute coronary syndrome and venous thromboembolism. Potential drug–disease interactions affecting patients with COVID-19 and comorbid cardiovascular diseases are also becoming a serious concern. In this Review, we summarize the current understanding of COVID-19 from basic mechanisms to clinical perspectives, focusing on the interaction between COVID-19 and the cardiovascular system. By combining our knowledge of the biological features of the virus with clinical findings, we can improve our understanding of the potential mechanisms underlying COVID-19, paving the way towards the development of preventative and therapeutic solutions.
引用
收藏
页码:543 / 558
页数:15
相关论文
共 266 条
  • [41] McGoogan JM(2020)Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Nat. Rev. Drug Discov. 311 187-422
  • [42] Ruan Q(2003)Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study Circulation 62 420-915
  • [43] Yang K(2003)Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study Lancet 8 911-426
  • [44] Wang W(2020)Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020 China CDC Wkly 22 413-625
  • [45] Jiang L(2020)Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy JAMA 11 618-353
  • [46] Song J(2020)Clinical characteristics of COVID-19 in New York City N. Engl. J. Med. 39 345-1210
  • [47] Shi S(2020)Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state JAMA 378 1205-204
  • [48] Guo T(2020)COVID-19 in critically ill patients in the Seattle region — case series N. Engl. J. Med. 28 195-2480
  • [49] Shi S(2020)Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy JAMA 128 2478-1879
  • [50] Riphagen S(2020)Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area JAMA 382 1867-1866